Royalty Pharma plc (RPRX) announced that it has acquired the final portion of PTC Therapeutics' remaining royalty interest in Roche's Evrysdi. The transaction includes an upfront payment of $240 million and up to $60 million in sales-based milestone payments.
Following the completion of this deal, Royalty Pharma will own 100% of the tiered royalty paid by Roche on worldwide net sales of Evrysdi. The royalty structure entitles Royalty Pharma to 8% on sales up to $500 million, 11% on sales between $500 million and $1 billion, 14% on sales between $1 billion and $2 billion, and 16% on sales exceeding $2 billion.
Royalty Pharma will begin receiving the increased royalty in the first quarter of 2026, based on Evrysdi product sales recorded in the fourth quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.